BioXcel Therapeutics, Inc.
BTAI evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Market Cap:
- $2.3M
- Lead Asset:
- bxcl501 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for BTAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BTAI
BioXcel Therapeutics (BTAI) is a biopharmaceutical company using AI to develop neuroscience medicines, with its only approved product IGALMI (dexmedetomidine) for acute agitation and a pipeline including BXCL701 for prostate cancer and BXCL501 for Alzheimer's agitation and opioid withdrawal.
Key risk: Negative equity and net loss
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 15 clinical trials for BioXcel Therapeutics, Inc..
Similar companies
BioXcel Therapeutics (BTAI) is a biopharmaceutical company using AI to develop neuroscience medicines, with its only approved product IGALMI (dexmedetomidine) for acute agitation and a pipeline including BXCL701 for prostate cancer and BXCL501 for Alzheimer's agitation and opioid withdrawal.
- FDA accepted sNDA for IGALMI in the at-home (outpatient) setting for acute agitation associated with bipolar disorders or schizophrenia, with a PDUFA date of November 14, 2026 [news · 2026-04-01]
- Cash & equivalents of $12.8M, total revenue of $0.2M, net income of -$14.7M, shareholders' equity of -$115.5M, and total debt of $107.2M as of 2026-06-30 [sec]
- BXCL501 (dexmedetomidine) is in Phase 3 for agitation associated with Alzheimer's dementia and showed positive Phase 2 topline results for opioid withdrawal in a NIDA-funded study [news · 2026-03-05]
- Pipeline includes BXCL701, an oral innate immune activator in Phase 3 for prostate cancer, facing 19 competitors [pipeline]
- Market assessment for IGALMI in the at-home setting estimates up to 86 million addressable annual episodes [news · 2026-03-27]
What works
- IGALMI is already FDA-approved for acute agitation in inpatient settings, providing a commercial foundation and regulatory experience [pipeline]
- The at-home label expansion for IGALMI targets a large market with no FDA-approved options, supported by a third-party assessment estimating up to 86 million annual episodes [news · 2026-03-27]
- BXCL501 has demonstrated clinical benefits in two distinct large-market indications (Alzheimer's agitation and opioid withdrawal), diversifying pipeline risk [news · 2026-03-05]
What to weigh
- The company has negative shareholders' equity of -$115.5M and a net loss of -$14.7M as of 2026-06-30, indicating sustained financial losses [sec]
- Cash & equivalents of only $12.8M as of 2026-06-30 may limit operational runway without additional financing or revenue [sec]
- Total debt of $107.2M as of 2026-06-30 significantly exceeds cash on hand, creating financial leverage risk [sec]
- BXCL701 faces a competitive landscape with 19 competitors, including large players like Pfizer, in Phase 2/3 for prostate cancer [pipeline]
From the filings
Quoted directly from source documents.
FDA accepted sNDA for IGALMI at-home use with PDUFA date of November 14, 2026
“the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI . The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.”
News · April 1, 2026
BXCL501 showed positive Phase 2 results for opioid withdrawal
“BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms”
News · March 5, 2026
Market assessment estimates up to 86 million addressable annual episodes for IGALMI at-home
“Analysis of market research revealed up to 86 million addressable annual episodes that may require treatment.”
News · March 27, 2026
Risks & what to watch (4)›
Key risks
- Negative equity and net loss — Shareholders' equity of -$115.5M and net loss of -$14.7M as of 2026-06-30 indicate sustained financial losses [sec]
- Low cash runway — Cash & equivalents of $12.8M as of 2026-06-30 may be insufficient to fund operations without new financing [sec]
- High debt burden — Total debt of $107.2M as of 2026-06-30 far exceeds cash on hand, increasing financial risk [sec]
- Competitive pipeline pressure — BXCL701 faces 19 competitors in prostate cancer, including Pfizer, in Phase 2/3 [pipeline]
What to watch
- PDUFA decision on IGALMI at-home sNDA on November 14, 2026 [news · 2026-04-01]
- Commercial launch plans and revenue generation from IGALMI if approved for at-home use [news · 2026-03-27]
- Progress of BXCL501 Phase 3 TRANQUILITY program for Alzheimer's agitation [news · 2026-03-27]
- Financial sustainability given negative equity and low cash reserves [sec]
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run BioXcel Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioXcel Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$15M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$7.3M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 1,936,760 | $2.6M |
| armistice capital, llc | 1,910,076 | $2.6M |
| oaktree capital management lp | 241,188 | $323K |
| geode capital management, llc | 230,168 | $309K |
| vanguard capital management llc | 207,339 | $278K |
| jones financial companies lllp | 131,789 | $166K |
| man group plc | 96,473 | $129K |
| state street corp | 92,118 | $123K |
| fmr llc | 90,300 | $121K |
| vanguard fiduciary trust co | 84,921 | $114K |
Showing top 10 of 39 institutional holders of BioXcel Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 16.0%
- Days to cover
- 4.0
- Shares short
- 4,243,441
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BTAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioXcel Therapeutics, Inc.?
BioXcel Therapeutics (BTAI) is a biopharmaceutical company using AI to develop neuroscience medicines, with its only approved product IGALMI (dexmedetomidine) for acute agitation and a pipeline including BXCL701 for prostate cancer and BXCL501 for Alzheimer's agitation and opioid withdrawal.
What is BioXcel Therapeutics, Inc.'s lead drug candidate?
BioXcel Therapeutics, Inc.'s most advanced tracked candidate is bxcl501 (Phase 3) for Agitation; Agitation,Psychomotor.
Who is the CEO of BioXcel Therapeutics, Inc.?
Dr. Vimal D. Mehta Ph.D. is the chief executive officer of BioXcel Therapeutics, Inc. (BTAI).
Where is BioXcel Therapeutics, Inc. headquartered?
BioXcel Therapeutics, Inc. (BTAI) is headquartered in New Haven, CT, United States.
What therapeutic areas does BioXcel Therapeutics, Inc. focus on?
BioXcel Therapeutics, Inc. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.